CCTG Senior Investigator Dr. Rushton is a Medical Oncologist based in Ottawa, Ontario, a Senior Investigator with the Canadian Cancer Trials Group in the IND program and an adjunct assistant professor in the Faculty of Health Sciences at Queen's University. She completed training in Internal Medicine and Medical Oncology at the University of Ottawa from 2012 - 2018. She then completed a Master's in Public Health from the University of California Berkeley (class of 2021) as well as spent time as a research fellow at CCTG working in both IND and Phase 3 trials 2019/2020. Her area of clinical focus is in breast cancer. She joined CCTG as a Senior Investigator in September 2021 where she is working on early phase trials in advanced breast cancer. She splits her time equally between CCTG and clinical practice in Ottawa. Areas of Expertise: Breast cancer Cardio-oncology Early phase clinical trials Current Trials: IND 234, IND 237, IND 241 Top publications: 1. S.F. Dent, J. Botros, M. Rushton, O. Aseyev, M., M. Levine, W.R. Parulekar, P. O'Brien, M. Burnell, K.I. Pritchard, B.E. Chen, L.E. Shepherd. Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The CCTG (NCIC CTG) MA.21 experience. Accepted for publication in Breast Cancer Treatment and Research, July 2020 https://pubmed.ncbi.nlm.nih.gov/32940847/ 2. M Rushton, I Lima, M Tuna, C Johnson, J Ivars, S Hawken, S Dent. The impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada. Journal National Cancer Institute, published 28 April 2020. https://doi.org/10.1093/jnci/djaa054 1. Peng J, Rushton M, Johnson C, Brezden-Masley C, Sulpher, J, Chiu MG, Graham I, Dent S. An international survey of health care providers’ knowledge of cardiac complications of cancer treatments. Cardio-Oncology 5, 12 (2019) doi:10.1186/s40959-019-0049-2 https://pubmed.ncbi.nlm.nih.gov/32154018/
